Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 5, 2019updated 23 Dec 2019 9:33am

Denali begins dosing Parkinson’s patients in Phase Ib trial

Denali Therapeutics has started dosing patients in a Phase Ib clinical trial evaluating DNL151 for the treatment of Parkinson’s disease.

Denali Therapeutics has started dosing patients in a Phase Ib clinical trial evaluating DNL151 for the treatment of Parkinson’s disease.

DNL151 is a small molecule leucine-rich repeat kinase 2 (LRRK2) inhibitor. LRRK2 regulates lysosomal function and its inhibition is expected to restore the impaired function and slow disease progression in Parkinson’s patients.

The multi-centre, randomised, placebo-controlled, double-blind Phase Ib study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of various oral doses of the drug candidate over 28 days.

In addition, target and pathway engagement biomarkers will be monitored, along with select exploratory clinical endpoints.

The trial will enrol around 24 mild to moderate Parkinson’s patients, irrespective of their genetic LRRK2 mutation status. Participants will be treated with a low or high dose of DNL151 or placebo.

“We are excited to evaluate DNL151 in Parkinson’s disease patients.”

Results from the Phase Ib trial are expected to be presented early next year.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Denali Therapeutics CMO Carole Ho said: “Based on data generated from our prior study in healthy volunteer subjects, we are excited to evaluate DNL151 in Parkinson’s disease patients.

“We believe that this study will provide additional important safety and biomarker data in patients to inform the choice between either DNL151 or DNL201 for potential registrational trials.”

The company also announced the launch of a patient engagement website, EngageParkinsons.com, which offers information about the neurodegenerative disease.

The website also explains the biomarker-driven approach used by the company to discover and develop investigational drugs for patients with Parkinson’s. It also provides information on clinical trials being conducted by the company.

Besides DNL151, Denali is studying DNL201 for the treatment of Parkinson’s patients with and without LRRK2 mutations.

In February this year, the company started dosing in a separate Phase Ib study of DNL747 for Alzheimer’s disease patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU